BGB-290: A highly potent and specific PARP1/2 inhibitor potentiates antitumor activity of chemotherapeutics in patient biopsy derived SCLC models

被引：8

作者：

Tang, Zhiyu ^{[1
]}

Liu, Ye ^{[1
]}

Zhen, Qin ^{[1
]}

Ren, Bo ^{[1
]}

Wang, Hexiang ^{[1
]}

Shi, Zhenyan ^{[1
]}

Gong, Wenfeng ^{[1
]}

Liu, Yong ^{[1
]}

Wang, Xing ^{[1
]}

Gao, Yajuan ^{[1
]}

Yu, Fenglong ^{[1
]}

Wu, Yiyuan ^{[1
]}

Jiang, Bing ^{[1
]}

Sun, Xuebing ^{[1
]}

Wei, Min ^{[1
]}

Zhou, Changyou ^{[1
]}

Luo, Lusong ^{[1
]}

Li, Zhengxiang ^{[2
]}

Yu, Jiangyong ^{[2
]}

Zhao, Jun ^{[2
]}

Wang, Jie ^{[2
]}

Wang, Lai ^{[1
]}

机构：

[1] BeiGene Inc, Beijing, Peoples R China

[2] Beijing Canc Hosp, Beijing, Peoples R China

来源：

CANCER RESEARCH | 2015年 / 75卷

关键词：

D O I：

10.1158/1538-7445.AM2015-1653

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1653

引用

页数：2

共 10 条

[1] Inhibition of PARP activity by BGB-290 potentiates efficacy of temozolomide in patient derived xenografts of glioblastoma multiforme
Gupta, Shiv K.
Carlson, Brett L.
Schroeder, Mark A.
Bakken, Katrina K.
Tuma, Ann C.
Sarkaria, Jann N.
CANCER RESEARCH, 2015, 75
[2] Safety, antitumor activity, and pharmacokinetics (PK) of pamiparib (BGB-290), a PARP1/2 inhibitor, in patients (pts) with advanced solid tumours: Updated phase I dose-escalation/expansion results
Voskoboynik, M.
Mileshkin, L.
Gan, H.
Millward, M.
Au-Yeung, G.
Meniawy, T. M.
Kichenadasse, G.
Zhang, K.
Zhang, M.
Mu, S.
Lickliter, J. D.
ANNALS OF ONCOLOGY, 2019, 30
[3] A phase I dose-escalation study of BGB-290, a novel PARP1/2 selective inhibitor in patients with advanced solid tumors.
Lickliter, Jason D.
Gan, Hui Kong
Meniawy, Tarek
Yang, Jason
Wang, Lai
Luo, Lusong
Lu, Ni
Millward, Michael
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[4] Preliminary results of pamiparib (BGB-290), a PARP1/2 inhibitor, in combination with temozolomide (TMZ) in patients (pts) with locally advanced or metastatic solid tumors
Johnson, M.
Galsky, M.
Barve, M.
Goel, S.
Park, H.
Du, B.
Mu, S.
Ramakrishnan, V.
Wood, K.
Wang, V.
Lakhani, N.
ANNALS OF ONCOLOGY, 2018, 29 : 138 - 138
[5] The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models
Herencia-Ropero, Andrea
Llop-Guevara, Alba
Staniszewska, Anna D.
Domenech-Vivo, Joanna
Garcia-Galea, Eduardo
Moles-Fernandez, Alejandro
Pedretti, Flaminia
Domenech, Heura
Rodriguez, Olga
Guzman, Marta
Arenas, Enrique J.
Verdaguer, Helena
Calero-Nieto, Fernando J.
Talbot, Sara
Tobalina, Luis
Leo, Elisabetta
Lau, Alan
Nuciforo, Paolo
Dienstmann, Rodrigo
Macarulla, Teresa
Arribas, Joaquin
Diez, Orland
Gutierrez-Enriquez, Sara
Forment, Josep V.
O'Connor, Mark J.
Albertella, Mark
Balmana, Judith
Serra, Violeta
GENOME MEDICINE, 2024, 16 (01):
[6] BGB-283: a novel RAF Dimer inhibitor, displays potent antitumor activity in HCC patient derived xenograft models
Tang, Zhiyu
Liu, Yong
Jiang, Beibei
Gao, Yajuan
Gong, Wenfeng
Wang, Xing
Su, Dan
Yu, Fenglong
Liu, Ye
Wei, Min
Wang, Lai
CANCER RESEARCH, 2016, 76
[7] Antitumor activity of the WEE1 inhibitor AZD1775 as a monotherapy and in combination with the PARP inhibitor olaparib in patient-derived explant (PDX) models
O'Connor, M. J.
Odedra, R.
Palakurthi, S.
Hughes, A.
Lai, Z.
Kirschmeier, P.
Zeng, Q.
Zhou, S.
Dharma, S.
Ivanova, E.
Wang, A.
Pierce, A. J.
Yates, J.
Powell, S.
Dougherty, B.
Barrett, J. C.
English, J.
Jewsbury, P.
Matulonis, U. A.
Liu, J. F.
EUROPEAN JOURNAL OF CANCER, 2016, 69 : S142 - S142
[8] Potent antitumor activity of XL184 (cabozantinib), a c-MET and VEGFR2 inhibitor, in colorectal cancer patient-derived tumor explant models.
Atreya, Chloe E.
Song, Eun-Kee
Messersmith, Wells
Purkey, Alicia
Bagby, Stacey
Quackenbush, Kevin
Kelley, Robin K.
Kwak, Eunice
Ryan, David
Venook, Alan
Arcaroli, John J.
CANCER RESEARCH, 2013, 73 (08)
[9] BLU-222, a potent and highly selective CDK2 inhibitor, demonstrates antitumor activity as monotherapy and as combination treatment in CCNE1-aberrant endometrial cancer models
House, Nealia
Brown, Victoria
Yuan, Liang
Chen, Maxine
Lee, Stephanie
Wu, Rentian
Muthuswamy, Lakshmi
Ribich, Scott
Ramsden, Philip
Faia, Kerrie
CANCER RESEARCH, 2024, 84 (06)
[10] Potent antisense pharmacology of highly optimized antisense oligonucleotides in multiple transgenic, spontaneous and patient derived xenograft models of cancer reveals antitumor activity for the non-coding RNA MALAT-1.
Hsu, Jeff
He, Guobin
Bhattacharjee, Gourab
Zhou, Tianyuan
May, Chris
Monia, Brett P.
Kim, Youngsoo
MacLeod, A. Robert
CANCER RESEARCH, 2012, 72

← 1 →